Maurizio Morri – Science Blog

recent posts

about

  • A Major Step Toward an HIV Cure: Dormant Virus Cells Finally Exposed

    In what may be the most promising development in HIV research in years, scientists at Australia’s Doherty Institute have announced a breakthrough that could bring us closer than ever to a cure. The team has developed a new type of lipid nanoparticle, called LNP X, that can deliver messenger RNA directly into the body’s hidden reservoirs of HIV.

    The challenge with curing HIV has never been just about suppressing the virus. Antiretroviral therapy can already reduce viral loads to undetectable levels. The real problem is what remains. Dormant white blood cells quietly harbor HIV in a latent state, invisible to the immune system and untouched by standard treatments. These so called viral reservoirs allow HIV to rebound the moment treatment is stopped.

    LNP X appears to change that. This specially engineered lipid nanoparticle is able to carry mRNA into these silent cells and trigger them to reveal the virus inside. Once exposed, the infected cells become visible to the immune system and can be destroyed or treated directly. The strategy is sometimes called kick and kill. It has been studied before, but until now, the field lacked a delivery tool precise and safe enough to reach those deeply hidden cells.

    According to lead scientist Professor Sharon Lewin, the results are unlike anything seen before in HIV cure research. LNP X is able to access tissues that were previously off limits, and the immune system can now see what it could not see before. What was once thought biologically impossible is now becoming a realistic path forward.

    The team hopes to move into clinical trials soon. If early human results match what has been seen in the lab, this could mark the beginning of the end for a virus that has taken the lives of more than thirty five million people over four decades. For those currently living with HIV, it offers something new. Not just lifelong control, but the possibility of permanent freedom from the virus.

    You can read the full article here:

    https://nypost.com/2025/06/05/health/doctors-near-hiv-cure-with-previously-impossible-discovery/

  • Do Plants Hear Us? New Research Shows Buzzing Bees Make Flowers More Nectar Rich

    A team of scientists from the University of Turin has uncovered something extraordinary about flowers. Led by zoologist Francesca Barbero, the group discovered that snapdragon plants can actually respond to the sound of pollinators. When these flowers were exposed to recordings of buzzing bees, they quickly began producing more nectar, and that nectar had a higher sugar content.

    The response was surprisingly fast. Within just three minutes of hearing the buzz of snail shell bees, the plants changed the quality of their nectar. This was not a random reaction. When the same flowers were exposed to other sounds, like ambient noise or the buzzing of insects that do not pollinate them, they stayed quiet. Only the specific sound of their preferred pollinators triggered the response.

    Scientists believe that the flowers may be using vibration sensitive cells called mechanoreceptors to detect the buzzing. These receptors might work like tiny biological microphones, tuned to respond to the unique frequency of a bee’s wings.

    This discovery suggests that plants are far more sensitive and responsive to their environment than we thought. They are not passive. They listen, and when they hear something important, they react.

    The research also hints at future uses in farming. If sound can influence nectar production, then sound could also be used to boost pollination. Imagine orchards playing the hum of bees to encourage flowers to prepare for real visitors, naturally improving fruit and seed production.

    What was once thought of as silent, still life turns out to be full of sensing and subtle communication. Plants are not speaking in the way we do, but they are definitely listening.

    Read more here:

    https://www.theguardian.com/environment/2025/may/21/plants-produce-more-nectar-when-they-hear-bees-buzzing-scientists-find

  • The Science Behind Music as a Universal Language

    The idea that music can be understood and felt by people everywhere, no matter what language they speak, is more than just a poetic thought. Scientists are now offering solid proof that music truly is a universal language.

    A large study from Harvard University looked at over one hundred years of music from more than three hundred cultures. The results were clear. People from different parts of the world could tell what kind of song they were hearing just by listening. Whether it was a lullaby, a love song, a dance tune, or a healing chant, listeners could identify the purpose based only on how it sounded. This shows that certain emotions and intentions come through in music without needing words.

    Even when the musical styles are different, many cultures use similar tools. The same kinds of rhythms, scales, and melodies show up again and again. These patterns seem to tap into something shared in how humans hear and feel sound. It is not just about training or background — it is something deeper, something built into how we experience the world.

    Brain scans are helping confirm this. When people listen to music, no matter where they come from, their brains light up in the same areas. Music activates the parts of the brain that handle emotion, memory, and reward. That means a melody written in one corner of the world can move someone on the other side of the planet in the same way.

    Science is now backing up what musicians and listeners have always known. Music is more than entertainment. It is a way of feeling understood. A way of expressing joy, grief, longing, and love that crosses all borders.

    You can read more about the research here:

    https://www.discovermagazine.com/mind/scientists-find-evidence-that-music-really-is-a-universal-language

    https://phys.org/news/2018-01-music-universal-language.html

  • Cassiopeia A Revealed: A Stunning Portrait of Stellar Death and Rebirth

    A breathtaking new image from NASA offers one of the most detailed looks yet at a supernova remnant — and it is nothing short of cosmic art. Scientists using the Chandra X-ray Observatory and the James Webb Space Telescope have joined forces to study Cassiopeia A, the remains of a massive star that exploded over 300 years ago. The result is a vivid, multi-wavelength composite that captures the extraordinary complexity of what happens when a star dies.

    Cassiopeia A lies about 11,000 light-years from Earth in the constellation Cassiopeia. What makes this remnant so valuable to astronomers is that it is close, relatively young, and still unfolding before our eyes. Each layer, shockwave, and filament tells a story about the life of the original star and the forces unleashed in its final moments.

    The new image combines infrared data from JWST with X-ray observations from Chandra, revealing features never seen in such clarity. One of the most eye-catching is a strange, twisting structure near the center, informally named the “Green Monster” for its eerie glow. This feature may be a region of cooler gas or a dense fragment of the progenitor star — and it is helping researchers piece together the chaotic internal structure left after the explosion.

    By studying Cassiopeia A across multiple wavelengths, scientists can track how different elements like iron, silicon, and oxygen are dispersed through space. These are the same elements that eventually form new stars, planets, and even life. In a very real way, Cassiopeia A is a cosmic recycling plant — a violent, beautiful engine of renewal.

    Far from being just a static remnant, Cassiopeia A is dynamic. Its shockwaves are still expanding. Its gases are still glowing. And with instruments like JWST and Chandra working together, we are getting closer to understanding how stars die and how the building blocks of the universe are born.

    Explore the full image and learn more:

    https://science.nasa.gov/multimedia/june-2025

  • Mount Etna’s June 2025 Eruption: A Spectacular Yet Expected Display

    On June 2, 2025, Mount Etna, Europe’s most active volcano, erupted once again, captivating onlookers with a dramatic display of nature’s power. The eruption sent a massive plume of ash and smoke into the sky, prompting evacuations and raising concerns among tourists and locals alike. However, for those familiar with Etna’s behavior, such events are part of the volcano’s regular activity.

    The Eruption Event

    The eruption began around 10 a.m. local time, originating from the volcano’s southeast crater. It featured explosive activity, including lava fountains and pyroclastic flows—fast-moving currents of hot gas and volcanic matter. A significant ash cloud rose approximately 21,300 feet into the atmosphere, nearly twice the volcano’s height, and released substantial sulfur dioxide, contributing to volcanic smog with potential health risks. Despite the dramatic visuals and the temporary closure of nearby tourist trails, there were no reported injuries or significant damage. Flights in the region experienced minimal disruptions, and local authorities quickly implemented safety measures.

    Understanding Etna’s Activity

    Mount Etna’s frequent eruptions are a result of its unique geological positioning. Situated at the convergence of the African and Eurasian tectonic plates, the volcano is in a state of almost constant activity. This continuous movement allows magma to rise to the surface regularly, leading to frequent eruptions. Unlike some other volcanoes that have long periods of dormancy followed by catastrophic eruptions, Etna’s consistent activity often results in less violent outbursts.

    The June 2025 eruption, while visually impressive, aligns with Etna’s typical behavior. Its ongoing activity is closely monitored by volcanologists, ensuring that any potential threats to nearby communities are identified promptly. This vigilance allows for timely evacuations and minimal disruption to daily life in the surrounding areas.

    A Natural Spectacle

    While the eruption may have startled tourists and garnered international media attention, it’s essential to recognize that such events are part of Mount Etna’s natural cycle. The volcano has been erupting for hundreds of thousands of years, shaping the landscape of Sicily and contributing to the region’s rich soil and biodiversity. For locals, Etna’s eruptions are a familiar occurrence, and the community has adapted to coexist with this dynamic natural feature.

    In conclusion, Mount Etna’s June 2025 eruption serves as a reminder of the Earth’s ever-changing nature. While it may cause temporary disruptions, it’s a testament to the planet’s geological vitality and the resilience of the communities that thrive in its shadow.

    For more detailed information on the eruption, you can refer to the following sources:

  • Is Regeneron’s Acquisition of 23andMe a Turning Point for Consumer Genomics?

    Regeneron Pharmaceuticals has agreed to acquire the bankrupt genetic testing company 23andMe for 256 million dollars, signaling a significant shift in the consumer genomics landscape. The deal, finalized through a court-supervised auction, is expected to close in the third quarter of 2025, pending regulatory approvals.

    Under the agreement, Regeneron will acquire 23andMe’s core assets, including its Personal Genome Service, Total Health and Research Services, and a biobank containing genetic data from over 15 million users. Notably, the acquisition excludes 23andMe’s telehealth subsidiary, Lemonaid Health, which is set to be discontinued. 

    The acquisition comes after 23andMe filed for Chapter 11 bankruptcy in March 2025, following a decline in consumer demand and a significant data breach in 2023 that compromised sensitive genetic information of millions of customers. 

    Regeneron has pledged to uphold 23andMe’s existing privacy policies and comply with all applicable data protection laws. To address privacy concerns, a court-appointed independent overseer will assess the implications of the deal for consumer privacy, with findings to be reviewed by the court on June 17. 

    This acquisition marks a pivotal moment in the integration of consumer genetic data into pharmaceutical research, potentially accelerating the development of personalized medicine. However, it also raises important questions about data privacy and the ethical use of genetic information.

    For more details, you can read the full articles here:

    https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-buy-bankrupt-genetic-testing-firm-23andme-256-million-2025-05-19/

    https://www.ft.com/content/362bcad4-8f4a-42b4-ab86-38821d74352f

    https://www.nypost.com/2025/05/19/business/regeneron-pharmaceuticals-to-buy-23andme-and-its-genetic-data-for-256-million/

  • Can Targeting Brachyury Unlock New Treatments for Rare and Metastatic Cancers?

    A recent breakthrough from the Institute of Cancer Research in London could mark a turning point in how scientists approach some of the most difficult cancers. Led by professor Paul Workman, researchers have discovered a way to potentially drug a protein called brachyury, a target long considered out of reach.

    Brachyury plays a critical role in a rare type of cancer known as chordoma, which affects the spine and base of the skull. These tumors are notoriously hard to treat, often recurring after surgery and showing poor response to traditional therapies. For years, researchers believed that brachyury could not be targeted by drugs because of its structure and location inside the cell.

    That view is now changing. Using the UK’s Diamond Light Source synchrotron, Workman’s team was able to map precise pockets on the surface of brachyury. These pockets can potentially bind with small molecules, opening the possibility of developing drugs that interfere with the protein’s activity and disrupt the survival of cancer cells.

    This is more than just a promising lead for chordoma. Brachyury is also active in several types of metastatic cancer, where it is linked to invasion, resistance, and poor outcomes. If the new findings lead to a working drug, the impact could extend far beyond one disease.

    You can read the full article here:

    https://www.theguardian.com/science/2025/feb/15/british-professor-paul-workman-cancer-breakthrough-chordoma

    The work is still at an early stage but it reflects a renewed focus in biotech on tackling tough, overlooked targets with the right tools and deep structural insights. This is where real progress happens — slowly, precisely, and with lasting consequences.

  • Is Biotech Entering a New Era of Drug Discovery?

    While artificial intelligence gets much of the attention, a wave of innovation in biotechnology is quietly reshaping the future of medicine. From groundbreaking Alzheimer’s treatments to novel gene editing strategies, biotech companies are pushing forward with fresh approaches that promise to change how we discover and develop new drugs.

    In Australia, the company Actinogen Medical is advancing a new once-a-day pill called Xanamem, designed to target cortisol, the stress hormone linked to memory loss and cognitive decline. Unlike many current treatments, Xanamem aims to address the root biological causes of Alzheimer’s disease. The World Health Organization recently recognized it as a first in class drug. So far, over four hundred people have received the treatment, showing promising improvements in memory, focus, and mood. A new trial involving two hundred twenty participants is underway in both Australia and the United States, with the goal of gaining full regulatory approval.

    You can read the full story here:

    https://www.couriermail.com.au/lifestyle/alzheimers-wonder-drug-onceaday-pill-could-halt-disease/news-story/dd50d2159e823f543dbe297b3b329005

    Meanwhile, UK-based Basecamp Research is exploring a completely different path. By collecting environmental DNA from some of the most remote places on Earth, they are building a massive genomic database that is already helping scientists design better proteins and explore rare genetic sequences. The team has discovered more than one million previously unknown species. Their work is now focused on programmable enzymes called large serine recombinases, which could allow more precise and flexible gene editing. These tools may open the door to next-generation cancer therapies and highly targeted gene repair strategies.

    More about their project here:

    https://www.ft.com/content/9765ab86-0156-4901-b6ec-fbee465ab819

    These breakthroughs show that biotech is not just catching up but actively leading in areas where traditional pipelines have stalled. The future of drug discovery looks more diverse, more ecological, and more tuned to the complexity of human biology than ever before.

  • New Test Uses Machine Learning to Personalize Prostate Cancer Treatment

    A major breakthrough in cancer care is making headlines. Scientists from the US, UK, and Switzerland have developed a cutting-edge test that predicts which men with aggressive, non-metastatic prostate cancer are most likely to benefit from the drug abiraterone. This is significant because while abiraterone can save lives, it also causes serious side effects such as high blood pressure, diabetes, and heart complications.

    Until now, doctors had no reliable way to know who should receive the drug. This new test, powered by machine learning, changes that. It analyzes digital images of tumor biopsy samples and identifies a specific biomarker that indicates whether a patient is likely to respond to treatment.

    In a study involving over one thousand men, the test found that twenty five percent of them had this biomarker. For these patients, abiraterone reduced the risk of death within five years from seventeen percent to nine percent. For the rest, the drug showed little to no effect, meaning they could avoid unnecessary treatment and side effects.

    The test is designed to work with routine clinical data and can easily be added to existing hospital workflows. It promises to make prostate cancer treatment more precise, sparing patients who do not need aggressive therapies and ensuring those who do get the help they need.

    Researchers also hope the findings will encourage broader approval of abiraterone for early-stage use, especially in the UK where its application has been limited. With this test, the decision becomes more scientific, more ethical, and far more personal.

    Read more here:

    https://www.theguardian.com/society/2025/may/30/new-ai-test-can-predict-which-men-will-benefit-from-prostate-cancer-drug

  • AI Simulates 500 Million Years of Evolution to Create a Novel Fluorescent Protein

    In a groundbreaking fusion of artificial intelligence and evolutionary biology, researchers at EvolutionaryScale and the Arc Institute have developed a novel fluorescent protein, esmGFP, using their advanced AI model, ESM3. This achievement marks a significant milestone in computational biology, demonstrating the potential of AI to simulate extensive evolutionary processes and design functional proteins beyond those found in nature.

    ESM3, a multimodal generative language model, was trained on an extensive dataset comprising over 3.15 billion protein sequences, 236 million protein structures, and 539 million protein annotations. This training enabled the model to understand and predict the sequence, structure, and function of proteins, effectively simulating 500 million years of molecular evolution in silico.

    The researchers prompted ESM3 to design a green fluorescent protein (GFP), a type of protein known for its ability to emit light and widely used as a marker in molecular biology. The AI-generated protein, esmGFP, shares only 58% sequence similarity with its closest natural counterpart, a fluorescent protein from the bubble-tip sea anemone (Entacmaea quadricolor). Despite this significant divergence, esmGFP was synthesized and successfully exhibited fluorescence in laboratory tests, validating the model’s capability to design functional proteins that nature has not evolved.

    This advancement holds immense promise for various applications, including drug discovery, environmental monitoring, and synthetic biology. The ability to design proteins with specific functions could lead to the development of new enzymes for breaking down plastics, novel therapeutics, and tools for exploring protein evolution.

    As someone deeply engaged in the intersection of AI and biology, the development of esmGFP underscores the transformative potential of integrating computational models with biological research. The capacity of AI to simulate vast evolutionary timescales and generate functional proteins exemplifies a paradigm shift in how we approach biological design and discovery.

    For more detailed information, you can refer to the original research article published in Science:

    https://www.science.org/doi/10.1126/science.ads0018

    And the official announcement from EvolutionaryScale:

    https://www.evolutionaryscale.ai/blog/esm3-release